American Journal of Epidemiology Advance Access originally published online on June 29, 2007
American Journal of Epidemiology 2007 166(5):518-526; doi:10.1093/aje/kwm124
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL CONTRIBUTIONS |
Insulin-like Growth Factors and Subsequent Risk of Mortality in the United States
1 Office of Analysis and Epidemiology, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD
2 Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
3 Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD
Correspondence to Dr. Sharon Saydah, Office of Analysis and Epidemiology, National Center for Health Statistics, Centers for Disease Control and Prevention, 3311 Toledo Road, Hyattsville, MD 20782 (e-mail: sharon{at}saydah.com; zle0{at}cdc.gov).
Received for publication October 30, 2006. Accepted for publication March 15, 2007.
Although numerous studies have explored the relation of insulin-like growth factor (IGF)-I and IGF-binding protein (BP) 3 with cancer and cardiovascular disease, only two previous studies are known to have looked at the association of IGF-I and IGF-BP3 with risk of mortality. The objective of this US study was to examine the risk of all-cause, heart disease, and cancer mortality associated with IGF-I and IGF-BP3 levels using data from the Third National Health and Nutrition Examination Survey (NHANES III) and NHANES III Mortality Study (n = 6,061) (1988–2000). The authors constructed proportional hazards models with age as the time scale to determine the association of baseline IGF-I and IGF-BP3 levels with subsequent mortality. After adjustment for baseline measures, there was no increased risk of all-cause, heart disease, or cancer mortality for the lower quartiles of IGF-I compared with the highest quartile. The adjusted relative hazard of all-cause mortality for the lowest quartile of IGF-BP3 compared with the highest quartile was 1.57 (95% confidence interval: 0.98, 2.52), and the trend for risk was significant (p = 0.0364), but there was no increased risk of heart disease or cancer mortality. Results suggest that the association of IGF-I and IGF-BP3 with mortality may differ from associations with incidence of disease.
heart diseases; insulin-like growth factor I; insulin-like growth factor binding protein 3; mortality; neoplasms; nutrition surveys
Abbreviations: BP, binding protein; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision; IGF, insulin-like growth factor; NHANES III, Third National Health and Nutrition Examination Survey
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. B Yeap, S A P. Chubb, K. K Y Ho, J. W S Setoh, K. A McCaul, P. E Norman, K. Jamrozik, and L. Flicker IGF1 and its binding proteins 3 and 1 are differentially associated with metabolic syndrome in older men Eur. J. Endocrinol., February 1, 2010; 162(2): 249 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Brugts, C. M. van Duijn, L. J. Hofland, J. C. Witteman, S. W.J. Lamberts, and J. A.M.J.L. Janssen IGF-I Bioactivity in an Elderly Population: Relation to Insulin Sensitivity, Insulin Levels, and the Metabolic Syndrome Diabetes, February 1, 2010; 59(2): 505 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jogie-Brahim, D. Feldman, and Y. Oh Unraveling Insulin-Like Growth Factor Binding Protein-3 Actions in Human Disease Endocr. Rev., August 1, 2009; 30(5): 417 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Glaser, N. Friedrich, R. Ewert, C. Schaper, M. Nauck, M. Dorr, H. Volzke, S. B. Felix, A. Krebs, H. Wallaschofski, et al. Association between Serum Insulin-Like Growth Factor (IGF) I and IGF Binding Protein-3 and Lung Function J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2452 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Friedrich, R. Haring, M. Nauck, J. Ludemann, D. Rosskopf, E. Spilcke-Liss, S. B. Felix, M. Dorr, G. Brabant, H. Volzke, et al. Mortality and Serum Insulin-Like Growth Factor (IGF)-I and IGF Binding Protein 3 Concentrations J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1732 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sierra-Johnson, R. M. Fisher, A. Romero-Corral, V. K. Somers, F. Lopez-Jimenez, J. Ohrvik, G. Walldius, M.-L. Hellenius, and A. Hamsten Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population Eur. Heart J., March 2, 2009; 30(6): 710 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Andreassen, I. Raymond, C. Kistorp, P. Hildebrandt, J. Faber, and L. O. Kristensen IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population Eur. J. Endocrinol., January 1, 2009; 160(1): 25 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Casazza, P. B. Higgins, J. R. Fernandez, M. I. Goran, and B. A. Gower Longitudinal Analysis of the Insulin-Like Growth Factor System in African-American and European American Children and Adolescents J. Clin. Endocrinol. Metab., December 1, 2008; 93(12): 4917 - 4923. [Abstract] [Full Text] [PDF]
|
|